Barricade Therapeutics
OperatingBarricade Therapeutics Corp
Biotech · Fort Worth, TX
A preclinical-stage biotechnology company developing BT-1501, an oral investigational therapy designed for APC-mutant colorectal cancer — a mutation commonly found in ~80% of CRC patients. Backed by $17 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and support/investment from the American Cancer Society, Barricade is preparing for first-in-human studies.
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common stock | 782 | 1 | 100.0% | — |
Principal holders% as the filing states it, Mar 2, 2026
- Neil Thapar839,563 Common Stock20.2%of votes
Sold to the crowd
- Reg CF · Mar 2026The same class and series of equity securities issued in the Qualified Financing$400.4K· 186 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
9 people
Dr. Thapar is a clinical pharmacologist with over 20 years of experience in oncology drug development. He completed a post-doctoral fellowship in oncology drug research & development at The University of Texas MD Anderson Cancer Center, focusing on translating scientific insights into innovative therapies. Prior to Barricade, Dr. Thapar worked on synthetic triterpenoid programs at Reata Pharmaceuticals as part of the company’s scientific and development teams during a period in which Reata completed an initial public offering and was later acquired by Biogen. His work is dedicated to advancing safer and more effective cancer treatments through evidence-based clinical pharmacology.
Mariam E. Morris supports Barricade’s executive leadership as a strategic advisor on corporate operations, financial strategy, and governance as the company scales. With more than 25 years of executive and advisory experience, she provides guidance across financial planning, capital strategy, compliance and public-company readiness, and complex transactions, including financings and M&A. She works closely with management and the Board to strengthen operational infrastructure, ensure financial rigor, and guide the company through key growth and transformation milestones.
Scott Jordan is a strategic advisor and investment banker with extensive experience in capital raising and successful exits, including public listings. He has served as CFO and CBO of both public and private biotech companies. Mr. Jordan’s expertise also includes business development and managing complex cross-border transactions.
Dr. Guillem is the President of Western Son Distillery and co-founder of CarGin Enterprises. He also serves on the boards of Barricade and Renibus Therapeutics.
Darlene Boudreaux is the CFO and Founder/CEO of PharmaFab. Previously, she served as Executive Director at TechFW. Mrs. Boudreaux has been instrumental in multiple successful exits, including ZS Pharma and Encore Vision. Darlene currently serves on Barricade’s Board of Directors, providing strategic guidance on corporate matters.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 1 annual reports (FY2025)
Missing: 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.